Francois Paris

Summary

Affiliation: CHU de Nantes
Country: France

Publications

  1. ncbi Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital ICO INSERM UMR 892, Nantes, France
    J Nucl Med 53:1836-46. 2012
  2. ncbi Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital, ICO René Gauducheau, Nantes, France
    Tumour Biol 33:601-6. 2012
  3. ncbi Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Rene Gauducheau Cancer Center, Nantes, France
    J Nucl Med 47:247-55. 2006
  4. ncbi Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Cancer Research Center, University Hospital, University of Nantes, Institut de Biologie, 9 quai Moncousu, Nantes, France
    Cancer 116:1118-25. 2010
  5. ncbi Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
    Françoise Kraeber-Bodéré
    INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
    J Nucl Med 51:624-31. 2010
  6. ncbi Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
    Pierre Yves Salaun
    Nuclear Oncology Department, Cancer Research Center, INSERM U892, Universite de Nantes, Nantes, France
    Cancer 116:1053-8. 2010
  7. ncbi Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis
    Stéphanie Bonnaud
    Inserm UMR892 Centre de Recherche en Cancérologie Nantes Angers, Nantes, France
    Cancer Res 70:9905-15. 2010
  8. ncbi Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development
    Ariane Desselle
    INSERM, UMR892, Nantes, France
    PLoS ONE 7:e45423. 2012
  9. ncbi A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity
    Nidia Alvarez-Rueda
    Centre de recherche en cancérologie de Nantes Angers, INSERM, Universite de Nantes, Nantes Atlantique Universites, U892, France
    PLoS ONE 6:e25220. 2011
  10. ncbi RhoA GTPase regulates radiation-induced alterations in endothelial cell adhesion and migration
    Matthieu Rousseau
    Inserm UMR U892, Centre de Recherche en Cancérologie Nantes Angers CRCNA, Institut de Recherche Thérapeutique IRT UN, Universite de Nantes, 8 quai Moncousu, BP 70721, F 44007, France
    Biochem Biophys Res Commun 414:750-5. 2011

Collaborators

  • Jacques Barbet
  • Marie Helene Gaugler
  • David M Goldenberg
  • Jean Francois Chatal
  • Sue Chua
  • Sauveur Michel Maira
  • Catherine Ansquer
  • Andreas Bikfalvi
  • Ludovic Ferrer
  • Gwenola Bougras
  • Gregory Delpon
  • Eric Frampas
  • Françoise Kraeber-Bodéré
  • Alain Faivre-Chauvet
  • Stéphanie Bonnaud
  • Pierre Yves Salaun
  • Ariane Desselle
  • Stephane Supiot
  • Jacques Aubry
  • Stéphane Birklé
  • Nidia Alvarez-Rueda
  • Colin Niaudet
  • Caroline Bodet-Milin
  • Vincent A Potiron
  • Denis Cochonneau
  • Tanguy Chaumette
  • Matthieu Rousseau
  • Isabelle Corre
  • Aurore Oudoux
  • Catherine Saï-Maurel
  • Stéphanie Leprieur
  • Béatrice Clémenceau
  • Nidia Alvarez Rueda
  • Rym Abderrhamani
  • Emmanuelle di Tomaso
  • Sophie Chiavassa
  • Eric Giang
  • Eliezer Shochat
  • Delphine Drui
  • Philippe Hulin
  • Marcel Stokkel
  • Eric Mirallie
  • Jean Lumbroso
  • James Nagarajah
  • Julien Fleurence
  • Nolwenn Dubois
  • Fergus Gleeson
  • Jean Tessier
  • Valerie Meresse Naegelen
  • Florent Hugonnet
  • Thomas Carlier
  • Carlos Trampal
  • Audrey Rodallec
  • Julie Saba
  • Jean Marie Mussini
  • Xavier Saulquin
  • Patrick Thomare
  • Richard Kolesnick
  • François Legoux
  • Zvi Fuks
  • Karine Estieu-Gionnet
  • Gerard Deleris
  • Anne Moreau
  • Géraldine Pottier
  • Julie Millour
  • Francois Davodeau
  • Laure Sabatier
  • Alain Faivre Chauvet
  • Véronique Sébille Rivain
  • Jean Philippe Vuillez
  • Anne Devillers
  • Chien Hsing Chang
  • Jean-Philippe Vuillez
  • Loic Campion
  • Chien-Hsing Chang
  • Caroline Rousseau

Detail Information

Publications13

  1. ncbi Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital ICO INSERM UMR 892, Nantes, France
    J Nucl Med 53:1836-46. 2012
    ....
  2. ncbi Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital, ICO René Gauducheau, Nantes, France
    Tumour Biol 33:601-6. 2012
    ....
  3. ncbi Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Rene Gauducheau Cancer Center, Nantes, France
    J Nucl Med 47:247-55. 2006
    ....
  4. ncbi Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Cancer Research Center, University Hospital, University of Nantes, Institut de Biologie, 9 quai Moncousu, Nantes, France
    Cancer 116:1118-25. 2010
    ..Pretargeted radioimmunotherapy has been the only innovative treatment modality convincingly showing some survival benefit when compared with a historical untreated control group...
  5. ncbi Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
    Françoise Kraeber-Bodéré
    INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
    J Nucl Med 51:624-31. 2010
    ..This study evaluated the toxicity and efficacy of combining radioimmunotherapy with thalidomide or a cyclopeptidic vascular endothelial growth inhibitor (CBOP11) in mice grafted with the TT human medullary thyroid cancer cell line...
  6. ncbi Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
    Pierre Yves Salaun
    Nuclear Oncology Department, Cancer Research Center, INSERM U892, Universite de Nantes, Nantes, France
    Cancer 116:1053-8. 2010
    ..The present pilot study evaluated toxicity and efficacy of RIT combined with bevacizumab in mice subcutaneously grafted with TT MTC cells...
  7. ncbi Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis
    Stéphanie Bonnaud
    Inserm UMR892 Centre de Recherche en Cancérologie Nantes Angers, Nantes, France
    Cancer Res 70:9905-15. 2010
    ..Our results provide strong pharmacologic and mechanistic proofs that S1P protects endothelial cells against acute radiation enteropathy...
  8. ncbi Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development
    Ariane Desselle
    INSERM, UMR892, Nantes, France
    PLoS ONE 7:e45423. 2012
    ..Our study demonstrates that Gb3 is a viable alternative target for immunotherapy and angiogenesis inhibition...
  9. ncbi A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity
    Nidia Alvarez-Rueda
    Centre de recherche en cancérologie de Nantes Angers, INSERM, Universite de Nantes, Nantes Atlantique Universites, U892, France
    PLoS ONE 6:e25220. 2011
    ..Hence, we investigated the distribution of OAcGD2 in human tissues using mAb 8B6 to study the cross-reactivity of mAb 8B6 with human tissues...
  10. ncbi RhoA GTPase regulates radiation-induced alterations in endothelial cell adhesion and migration
    Matthieu Rousseau
    Inserm UMR U892, Centre de Recherche en Cancérologie Nantes Angers CRCNA, Institut de Recherche Thérapeutique IRT UN, Universite de Nantes, 8 quai Moncousu, BP 70721, F 44007, France
    Biochem Biophys Res Commun 414:750-5. 2011
    ..These results highlight the role of RhoA GTPase in ionizing radiation-induced deregulation of essential endothelial functions linked to actin cytoskeleton...
  11. ncbi Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death
    Stéphanie Bonnaud
    Département de Recherche en Cancérologie, Institut National de la Sante et de la Recherche Medicale U601, Universite de Nantes, Faculte des Sciences, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 01, France
    Cancer Res 67:1803-11. 2007
    ....
  12. ncbi Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions
    Vincent A Potiron
    INSERM, UMR892, Nantes, France
    Radiother Oncol 106:138-46. 2013
    ..We investigated whether the novel PI3K/mTOR inhibitor BEZ235 might sensitize prostate cancer cells to radiation and reduce hypoxia-induced radioresistance...
  13. ncbi Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen
    Nidia Alvarez Rueda
    INSERM, Universite de Nantes, Nantes Atlantique Universités U601, Département de Recherche en Cancérologie, 9 quai Moncousu, F 44093 Nantes, France
    Clin Cancer Res 13:5613s-5620s. 2007
    ..We previously generated a mouse monoclonal antibody (mAb) specific for the tumor-associated GD2 ganglioside antigen. Here, we describe the development of a chimeric anti-GD2 mAb for more effective tumor immunotherapy...